Last reviewed · How we verify

Scilex Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Scilex Pharmaceuticals, Inc. pipeline: 2 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ZTlido ZTlido marketed
Lidocaine patch 1.8% Lidocaine patch 1.8% marketed Local anesthetic Voltage-gated sodium channels Pain management
SP-102 SP-102 phase 3 cannabinoid CB1 receptor Pain

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams Maternity Hospital · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Aligarh Muslim University · 1 shared drug class
  4. Aphios · 1 shared drug class
  5. Atlantic Health System · 1 shared drug class
  6. Aultman Health Foundation · 1 shared drug class
  7. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
  8. Abant Izzet Baysal University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Scilex Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Scilex Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scilex-pharmaceuticals-inc. Accessed 2026-05-16.

Related